<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538095</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-00252</org_study_id>
    <secondary_id>NCI-2012-00252</secondary_id>
    <secondary_id>COG-ADVL1115</secondary_id>
    <secondary_id>ADVL1115</secondary_id>
    <secondary_id>PADVL1115_A05PAMDREVW01</secondary_id>
    <secondary_id>CDR0000725371</secondary_id>
    <secondary_id>ADVL1115</secondary_id>
    <secondary_id>ADVL1115</secondary_id>
    <secondary_id>UM1CA097452</secondary_id>
    <nct_id>NCT01538095</nct_id>
  </id_info>
  <brief_title>Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors</brief_title>
  <official_title>A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of trebananib in treating patients
      with solid tumors that has returned after a period of improvement or does not respond to
      treatment, including central nervous system tumors. Trebananib may stop the growth of tumor
      cells by blocking blood flow to the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the maximum-tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of
      trebananib (AMG 386) administered as a weekly intravenous infusion to children with recurrent
      or refractory solid tumors.

      II. To determine the tolerability of the solid tumor MTD and/or RP2D of AMG 386 in children
      with central nervous system (CNS) tumors.

      III. To define and describe the toxicities of AMG 386 administered on this schedule.

      IV. To characterize the pharmacokinetics and immunogenicity of AMG 386 in children with
      refractory cancer.

      V. To measure changes in vascular permeability relative to baseline, evaluated by magnetic
      resonance imaging (MRI) perfusion, following AMG 386 administration in pediatric patients
      with CNS tumors.

      SECONDARY OBJECTIVES:

      I. To preliminarily define the antitumor activity of AMG 386 within the confines of a Phase 1
      study.

      II. To measure biologic markers of angiogenesis with potential for correlation with disease
      response.

      OUTLINE: This is a dose-escalation study (part 1) followed by a safety and imaging study
      (part 2).

      Patients receive trebananib intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 22.
      Treatment repeats every 28 days in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every 3 to
      6 months for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events as assessed by the National Cancer Institute (NCI) CTCAE v 4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>A descriptive summary of all toxicities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD at which fewer than one-third of patients experience dose limiting toxicity as assessed by NCI CTCAE version 4.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of trebananib</measure>
    <time_frame>At baseline, at days 1, 8, 15, and 22 of course 1</time_frame>
    <description>A descriptive analysis of PK parameters of trebananib will be performed to define systemic exposure, drug clearance, and other pharmacokinetic parameters. The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in vascular permeability relative to baseline as evaluated by MRI in patients with CNS tumors</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response assessed according to RECIST version 1.1</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Reported descriptively.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Circulating antiangiogenic protein and Tie2 expressing monocyte levels</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Reported descriptively and will utilize intra-patient variability estimated from two baseline blood samples.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Central Nervous System Neoplasm</condition>
  <condition>Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (trebananib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dynamic Contrast-Enhanced Magnetic Resonance Imaging</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (trebananib)</arm_group_label>
    <other_name>DCE MRI</other_name>
    <other_name>DCE-MRI</other_name>
    <other_name>DYNAMIC CONTRAST ENHANCED MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (trebananib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (trebananib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trebananib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (trebananib)</arm_group_label>
    <other_name>AMG 386</other_name>
    <other_name>Angiopoietin 1/2-Neutralizing Peptibody AMG 386</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Patients must have had histologic verification of non-CNS solid tumor
             malignancy at original diagnosis or relapse

          -  Part 2: Patients must have had histologic verification of CNS malignancy at original
             diagnosis or relapse except in patients with intrinsic brain stem tumors, optic
             pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid
             (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic
             gonadotropin (HCG)

          -  Patients must have either measurable or evaluable disease

          -  Patient's current disease state must be one for which there is no known curative
             therapy or therapy proven to prolong survival with an acceptable quality of life

          -  Karnofsky &gt;= 50% for patients &gt; 16 years of age and Lansky &gt;= 50% for patients =&lt; 16
             years of age; Note: neurologic deficits in patients with CNS tumors (Part 2 of the
             study) must have been relatively stable for at least 7 days prior to study enrollment;
             patients who are unable to walk because of paralysis, but who are up in a wheelchair,
             will be considered ambulatory for the purpose of assessing the performance score

          -  Patients must have fully recovered from the acute toxic effects of all prior
             anti-cancer chemotherapy

               -  Myelosuppressive chemotherapy: at least 21 days after the last dose of
                  myelosuppressive chemotherapy (42 days if prior nitrosourea)

               -  Hematopoietic growth factors: at least 14 days after the last dose of a
                  long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth
                  factor; for agents that have known adverse events occurring beyond 7 days after
                  administration, this period must be extended beyond the time during which adverse
                  events are known to occur; the duration of this interval must be discussed with
                  the study chair

               -  Biologic (anti-neoplastic agent): at least 7 days after the last dose of a
                  biologic agent; for agents that have known adverse events occurring beyond 7 days
                  after administration, this period must be extended beyond the time during which
                  adverse events are known to occur; the duration of this interval must be
                  discussed with the study chair

               -  Immunotherapy: at least 42 days after the completion of any type of
                  immunotherapy, e.g. tumor vaccines

               -  Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose
                  of a monoclonal antibody

               -  Radiation therapy (XRT): at least 14 days after local palliative XRT (small
                  port); at least 150 days must have elapsed if prior total-body irradiation (TBI),
                  craniospinal XRT or if &gt;= 50% radiation of pelvis; at least 42 days must have
                  elapsed if other substantial bone marrow (BM) radiation

               -  Stem cell infusion without TBI: no evidence of active graft vs host disease and
                  at least 56 days must have elapsed after transplant or stem cell infusion

          -  Peripheral absolute neutrophil count (ANC) &gt;= 1000/mm^3

          -  Platelet count &gt;= 100,000/mm^3 (transfusion independent, defined as not receiving
             platelet transfusions for at least 7 days prior to enrollment

          -  Patients with known bone marrow metastatic disease will be eligible for study provided
             they meet the required blood counts (may receive transfusions provided they are not
             known to be refractory to red cell or platelet transfusions)

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  0.6 mg/dL (1 to &lt; 2 years of age)

               -  0.8 mg/dL (2 to &lt; 6 years of age)

               -  1.0 mg/dL (6 to &lt; 10 years of age)

               -  1.2 mg/dL (10 to &lt; 13 years of age)

               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to &lt; 16 years of age)

               -  1.7 mg/dL (male) or 1.4 mg/dL (female) (&gt;= 16 years of age)

          -  Urine protein: =&lt; 30 mg/dL in urinalysis or =&lt; 1+ on dipstick, unless quantitative
             protein is &lt; 1,000 mg in a 24-hour urine sample

          -  Bilirubin (sum of conjugated + unconjugated) =&lt; 1.5 x upper limit of normal (ULN) for
             age

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 110
             U/L; for the purpose of this study, the ULN for SGPT is 45 U/L

          -  Serum albumin &gt;= 2 g/dL

          -  Shortening fraction of &gt;= 27% by echocardiogram OR ejection fraction of &gt;= 50% by
             gated radionuclide study

          -  No known cardiac disease

          -  No history of myocardial infarction, severe or unstable angina, peripheral vascular
             disease or familial corrected QT (QTc) prolongation

          -  Patients with seizure disorder may be enrolled if on anticonvulsants and well
             controlled

          -  Nervous system disorders (Common Terminology Criteria for Adverse Events version 4
             [CTCAE v 4]) resulting from prior therapy must be =&lt; grade 2

          -  For Part 2 only: No evidence of new CNS hemorrhage defined as more than punctate size
             and/or more than three foci of punctate hemorrhage on baseline magnetic resonance
             imaging (MRI) obtained within 14 days prior to study enrollment

          -  No evidence of active bleeding

          -  Prothrombin time (PT) and partial thromboplastin time (PTT) =&lt; 1.2 x upper limit of
             normal (ULN) and an international normalized ratio (INR) =&lt; 1.2

          -  A blood pressure (BP) =&lt; the 95th percentile for age, height, and gender, and not
             receiving medication for treatment of hypertension

          -  All patients and/or their parents or legally authorized representatives must sign a
             written informed consent; assent, when appropriate, will be obtained according to
             institutional guidelines

        Exclusion Criteria:

          -  Pregnant or breast-feeding women will not be entered on this study; pregnancy tests
             must be obtained in girls who are post-menarchal; males or females of reproductive
             potential may not participate unless they have agreed to use an effective
             contraceptive method for the duration of study participation, and for 6 months after
             completion of AMG 386 administration

          -  Patients receiving corticosteroids who have not been on a stable or decreasing dose of
             corticosteroid for at least 7 days prior to enrollment are not eligible

          -  Patients who are currently receiving another investigational drug are not eligible

          -  Patients who are currently receiving other anticancer agents are not eligible

          -  Patients who are receiving cyclosporine, tacrolimus, or other agents to prevent
             graft-versus-host disease post bone marrow transplant are not eligible for this trial

          -  Patients who are currently receiving therapeutic anticoagulation with heparin,
             low-molecular weight heparin, or Coumadin are not eligible for this trial

          -  Patients who are currently receiving aspirin, ibuprofen, or other non-steroidal
             anti-inflammatory drugs or anti-platelet agents are not eligible

          -  Patients who are receiving anti-hypertensive medications for control of blood pressure
             at the time of enrollment are not eligible for this trial

          -  Patients who have an uncontrolled infection are not eligible

          -  Patients who have received a prior solid organ transplantation are not eligible

          -  Patients who have had or are planning to have the following invasive procedures are
             not eligible:

               -  Major surgical procedure, laparoscopic procedure, open biopsy, or significant
                  traumatic injury within 28 days prior to enrollment

               -  Central line placement or subcutaneous port placement is not considered major
                  surgery but must be placed at least 3 days prior to enrollment for external lines
                  (e.g., Hickman or Broviac) and at least 7 days prior to enrollment for
                  subcutaneous port

               -  Core biopsy within 7 days prior to enrollment

               -  Fine-needle aspirate within 7 days prior to enrollment

          -  Patients with evidence of active bleeding: intratumoral hemorrhage by current imaging,
             or bleeding diathesis are not eligible

          -  Patients with a history (within 365 days prior to study enrollment) of arterial/venous
             thromboembolic events including transient ischemic attack (TIA) or cerebrovascular
             accident (CVA) are not eligible

          -  Patients with a history of hemoptysis within 42 days prior to study enrollment are not
             eligible

          -  For Part 2: Patients with CNS tumors and evidence of new CNS hemorrhage of more than
             punctate size and/or more than three foci of punctate hemorrhage on baseline MRI
             obtained within 14 days prior to study enrollment are not eligible; Note:
             echocardiogram (ECHO) gradient MRI sequences per institutional guidelines are required
             for patients with CNS tumors

          -  Patients who have a history of serious or non-healing wound, abdominal fistula,
             gastrointestinal ulcer or perforation, bone fracture, or intra-abdominal abscess
             within 28 days of study enrollment are not eligible

          -  Patients with known cardiac or peripheral vascular disease are not eligible

          -  Patients who, in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study are not eligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Leary</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University/Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChildrenÂ¿s Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2012</study_first_submitted>
  <study_first_submitted_qc>February 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>September 30, 2016</last_update_submitted>
  <last_update_submitted_qc>September 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trebananib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

